دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Flashback Foreword: Single-Agent Anti-Programmed Cell Death Protein 1 Therapy for Refractory Solid Tumors.
Maki, Robert G. MD, PhD 1,2,,
doi : 10.1200/JCO.22.02437
Volume 41(4) pgs. 713-940 February 1, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Brahmer, Julie R.; Drake, Charles G.; Wollner, Ira; Powderly, John D.; Picus, Joel; Sharfman, William H.; Stankevich, Elizabeth; Pons, Alice; Salay, Theresa M.; McMiller, Tracee L.; Gilson, Marta M.; Wang, Changyu; Selby, Mark; Taube, Janis M.; Anders, Robert; Chen, Lieping; Korman, Alan J.; Pardoll, Drew M.; Lowy, Israel; Topalian, Suzanne L.
doi : 10.1200/JCO.22.02270
Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.
Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?.
Kahl, Brad S. MD 1,,
doi : 10.1200/JCO.22.01501
Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward.
Kamihara, Junne MD, PhD 1,,; Collins, Natalie B. MD, PhD 1,
doi : 10.1200/JCO.22.01678
Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets.
Santa-Maria, Cesar A. MD 1,,; Wolff, Antonio C. MD 1,
doi : 10.1200/JCO.22.02217
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Ho, Alan L. MD, PhD 1,2,
doi : 10.1200/JCO.22.01408
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?.
Benjamin, David J. MD 1; Nagasaka, Misako MD, PhD 2,3,
doi : 10.1200/JCO.22.01199
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Westin, Jason MD, MS 1,,; Davis, R. Eric MD 1,; Feng, Lei MS 2; Hagemeister, Fredrick MD 1,; Steiner, Raphael MD 1,; Lee, Hun Ju MD 1,; Fayad, Luis MD 1,; Nastoupil, Loretta MD 1,; Ahmed, Sairah MD 1,; Rodriguez, Alma MD 1; Fanale, Michelle MD 1,3,; Samaniego, Felipe MD 1,; Iyer, Swaminathan P. MD 1,; Nair, Ranjit MD 1,; Oki, Yasuhiro MD 1,; Fowler, Nathan MD 1,; Wang, Michael MD 1,; Ma, Man Chun John PhD 1; Vega, Francisco MD 4,; McDonnell, Timothy MD 4; Pinnix, Chelsea MD, PhD 5,; Griffith, Donna RN 1; Lu, Yang MD 6,; Tewari, Sanjit MD 6,; Sun, Ryan PhD 2,; Scott, David W. MBChB, PhD 7,; Flowers, Christopher R. MD 1,; Neelapu, Sattva MD 1,; Green, Michael R. PhD 1,8,
doi : 10.1200/JCO.22.00597
Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL, particularly in the non-germinal center B-cell-like subset.
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.
Grob, Tim MD 1; Sanders, Mathijs A. PhD 1; Vonk, Christian M. MSc 1; Kavelaars, Fran[Cyrillic small letter es with descender]ois G. BSc 1; Rijken, Melissa BSc 1; Hanekamp, Diana W. PhD 1,2; Gradowska, Patrycja L. PhD 1; Cloos, Jacqueline PhD 2,; Floisand, Yngvar MD, PhD 3,; van Marwijk Kooy, Marinus MD, PhD 4; Manz, Markus G. MD 5; Ossenkoppele, Gert J. MD, PhD 2,; Tick, Lidwine W. MD, PhD 6; Havelange, Violaine MD, PhD 7,; Lowenberg, Bob MD, PhD 1,; Jongen-Lavrencic, Mojca MD, PhD 1; Valk, Peter J.M. PhD 1,,
doi : 10.1200/JCO.22.00715
The applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of FLT3-ITD during relapse.
Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.
Chung, Jiil PhD 1,2; Negm, Logine 1,2,3; Bianchi, Vanessa PhD 2; Stengs, Lucie 2; Das, Anirban MD 1,2,4,5; Liu, Zhihui Amy PhD 6,7; Sudhaman, Sumedha PhD 1,2,; Aronson, Melyssa MSc 8; Brunga, Ledia MD 1,9; Edwards, Melissa PhD 1; Forster, Victoria PhD 2; Komosa, Martin MSc 2; Davidson, Scott PhD 1,9; Lees, Jodi 1; Tomboc, Patrick MD 10,; Samuel, David MD 11; Farah, Roula MD 12; Bendel, Anne MD 13; Knipstein, Jeffrey MD 14,; Schneider, Kami Wolfe MSc 15,; Reschke, Agnes MD 16; Zelcer, Shayna MD 17; Zorzi, Alexandra MD 18; McWilliams, Robert MD 19,; Foulkes, William D. MD 20; Bedgood, Raymond MD 21; Peterson, Lindsay MD 22,; Rhode, Sara MSc 23,; Van Damme, An MD 24,; Scheers, Isabelle MD 25; Gardner, Sharon MD 26; Robbins, Gabriel MD 26; Vanan, Magimairajan Issai MD 27,28; Meyn, M. Stephen MD, PhD 29,30,; Auer, Rebecca MD 31,; Leach, Brandie MSc 32,; Burke, Carol MD 32,; Villani, Anita MD 4; Malkin, David MD 4,; Bouffet, Eric MD 4,; Huang, Annie MD, PhD 2,4,33; Taylor, Michael D. MD, PhD 2,34; Durno, Carol MD 8,35; Shlien, Adam PhD 1,9,33; Hawkins, Cynthia MD, PhD 2,9,36,; Getz, Gad PhD 37,38,39,40,; Maruvka, Yosef E. PhD 41,; Tabori, Uri MD 1,2,4,; on behalf of the International Replication Repair Deficiency Consortium
doi : 10.1200/JCO.21.02873
Diagnosis of Mismatch Repair Deficiency (MMRD) is crucial for tumor management and early detection in patients with the cancer predisposition syndrome constitutional mismatch repair deficiency (CMMRD).
Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/DICER1 Registry.
Schultz, Kris Ann P. MD 1,2,3,; Harris, Anne K. MPH 1,2,3; Nelson, Alexander T. BS 1,2,3,4; Watson, Dave PhD 5,; Lucas, John T. Jr MS, MD 6; Miniati, Doug MD 7; Stewart, Douglas R. MD 8,; Hagedorn, Kelly N. MD 9,; Mize, William MD 9; Kamihara, Junne MD, PhD 10,; Mitchell, Sarah G. MD 11; Wilson, David B. MD, PhD 12,; Gettinger, Katie CPNP 12; Rangaswami, Arun A. MD 13; Harney, Laura A. BSN 14; Rodriguez Galindo, Carlos MD 15; Bisogno, Gianni MD 16,; Dehner, Louis P. MD 17; Hill, D. Ashley MD 18,19,; Messinger, Yoav H. MD 1,2,3
doi : 10.1200/JCO.21.02925
Pleuropulmonary blastoma (PPB) is the most common primary lung neoplasm of infancy and early childhood. Type II and type III PPB have historically been associated with a poor prognosis.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington, Kevin J. PhD 1,,; Burtness, Barbara MD 2,; Greil, Richard MD 3,4,; Soulieres, Denis MD 5,; Tahara, Makoto MD 6,; de Castro, Gilberto Jr MD 7,; Psyrri, Amanda MD 8,; Brana, Irene MD 9,; Baste, Neus MD 9,; Neupane, Prakash MD 10,; Bratland, Ase PhD 11,; Fuereder, Thorsten MD 12,; Hughes, Brett G.M. MBBS 13,; Mesia, Ricard PhD 14,; Ngamphaiboon, Nuttapong MD 15,; Rordorf, Tamara MD 16; Wan Ishak, Wan Zamaniah MD 17,; Lin, Jianxin MS 18,; Gumuscu, Burak MD 18,; Swaby, Ramona F. MD 18,; Rischin, Danny MD 19,20,
doi : 10.1200/JCO.21.02508
Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented.
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Gallois, Claire MD 1,; Shi, Qian PhD 2,; Meyers, Jeffrey P. MD 2,; Iveson, Timothy MD 3,; Alberts, Steven R. MD, MPH 4; de Gramont, Aimery MD 5; Sobrero, Alberto F. PhD 6,; Haller, Daniel G. MD 7; Oki, Eiji MD 8,; Shields, Anthony Frank MD, PhD 9,; Goldberg, Richard M. MD 10,; Kerr, Rachel MD 11; Lonardi, Sara MD 12,; Yothers, Greg PhD 13,; Kelly, Caroline PhD 14; Boukovinas, Ioannis MD, PhD 15,; Labianca, Roberto MD 16,; Sinicrope, Frank A. MD 4,; Souglakos, Ioannis MD, PhD 17,; Yoshino, Takayuki MD 18,; Meyerhardt, Jeffrey A. MD, MPH 19,; Andre, Thierry MD, PhD 20,; Papamichael, Demetris MD 21,; Taieb, Julien MD, PhD 1,,
doi : 10.1200/JCO.21.02726
Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) could worsen the prognosis.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi, Kensei MD 1,,; Bang, Yung-Jue MD, PhD 2,; Iwasa, Satoru MD 3,; Sugimoto, Naotoshi MD 4,; Ryu, Min-Hee MD, PhD 5,; Sakai, Daisuke MD 6,; Chung, Hyun Cheol MD, PhD 7,; Kawakami, Hisato MD, PhD 8,; Yabusaki, Hiroshi MD 9; Lee, Jeeyun MD 10,; Shimoyama, Tatsu MD 11; Lee, Keun-Wook MD, PhD 12,; Saito, Kaku MSc, MBA 13,; Kawaguchi, Yoshinori MSc, MBA 13,; Kamio, Takahiro MD 13,; Kojima, Akihito MSc 14,; Sugihara, Masahiro PhD 14,; Shitara, Kohei MD 15,
doi : 10.1200/JCO.22.00575
To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis.
Gonzalez Serrano, Adolfo MD, MSc 1,; Laurent, Marie MD, PhD 1,2; Barnay, Thomas PhD 3; Martinez-Tapia, Claudia PhD 1; Audureau, Etienne MD, PhD 1,4; Boudou-Rouquette, Pascaline MD 5,; Aparicio, Thomas MD, PhD 6,; Rollot-Trad, Florence MD 7; Soubeyran, Pierre MD, PhD 8,; Bellera, Carine PhD 9,10,; Caillet, Philippe MD 1,11,12,; Paillaud, Elena MD, PhD 1,11,12,; Canoui-Poitrine, Florence MD, PhD 1,4
doi : 10.1200/JCO.22.01118
The intended clinical value of frailty screening is to identify unfit patients needing geriatric assessment (GA) and to prevent unnecessary GA in fit patients. These hypotheses rely on the sensitivity and specificity of screening tests, but they have not been verified.
Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.
Culakova, Eva PhD, MS 1; Mohile, Supriya G. MD, MS 2; Peppone, Luke PhD, MPH 1,2,; Ramsdale, Erika MD, MS 2,; Mohamed, Mostafa MBBCh 2,3; Xu, Huiwen PhD 4; Wells, Megan MPH 2,; Tylock, Rachael MS 2,; Java, Jim PhD 5; Loh, Kah Poh MBBCh, BAO, MS 2,; Magnuson, Allison DO, MS 2; Jamieson, Leah RN 6; Vogel, Victor MD 7; Duberstein, Paul R. PhD 8; Chapman, Benjamin P. PhD, MPH, MS 9; Dale, William MD, PhD 10; Flannery, Marie Anne PhD, RN 11,
doi : 10.1200/JCO.22.00738
Providing a geriatric assessment (GA) summary with management recommendations to oncologists reduces clinician-rated toxicity in older patients with advanced cancer receiving treatment. This secondary analysis of a national cluster randomized clinical trial (ClinicalTrials.
Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial.
Puts, Martine RN, PhD, FAAN 1,; Alqurini, Naser MD, MRCGP (INT) 2; Strohschein, Fay RN, PhD 3; Koneru, Rama MBBS, FRCPC, MHSc 4,; Szumacher, Ewa MD, FRCPC, MEd, CPC(HC) 5; Mariano, Caroline MD, FRCPC 6,; Monette, Johanne MD, MSc 7; Hsu, Tina MD, FRCPC, MMEd 8,; Brennenstuhl, Sarah MSW, PhD 1; McLean, Bianca MD 1,9; Wills, Aria BSc 1; Berger, Arielle MD 10; Amir, Eitan MD, PhD 11,12,; Romanovsky, Lindy MD, MSc (HQ) 10; Li, Anson MD, MSc 13; Mehta, Rajin MD, FRCPC, FRCPE 14; Krzyzanowska, Monika MD, MPH 11,; Elser, Christine MD, MPhil 11,12; Jang, Raymond MD, MSc 11,; Prica, Anca MD, MSc 11,; Wan-Chow-Wah, Doreen MDCM, FRCPC 7; Pitters, Eric BSc 1; Emmenegger, Urban MD 15,; Menjak, Ines B. MD, MSc, FRCPC 15,; Bergman, Simon MD, MSc 16; Lemonde, Manon RN, PhD 17; Breunis, Henriette CCRP 18; Beland, Francois PhD 19; Alibhai, Shabbir M.H. MD, MSc 20,
doi : 10.1200/JCO.22.01007
American Society of Clinical Oncology recommends that older adults with cancer being considered for chemotherapy receive geriatric assessment (GA) and management (GAM), but few randomized controlled trials have examined its impact on quality of life (QOL).
Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
Jayasekera, Jinani PhD 1,; Zhao, Amy MSc 2; Schechter, Clyde MD 3; Lowry, Kathryn MD 4; Yeh, Jennifer M. PhD 5; Schwartz, Marc D. PhD 2; O'Neill, Suzanne PhD 2,; Wernli, Karen J. PhD 6; Stout, Natasha PhD 7; Mandelblatt, Jeanne MD 2; Kurian, Allison W. MD, MSc 8,; Isaacs, Claudine MD 2,
doi : 10.1200/JCO.22.01342
Recent studies, including a meta-analysis of 88 trials, have shown higher than expected rates of recurrence and death in hormone receptor-positive breast cancer. These new findings suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer and breast cancer death in high-risk women.
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Kim, Joseph W. MD 1,,; McKay, Rana R. MD 2,; Radke, Marc R. BS 3; Zhao, Shilin PhD 4; Taplin, Mary-Ellen MD 5,; Davis, Nancy B. MD 6,; Monk, Paul MD 7,; Appleman, Leonard J. MD, PhD 8,; Lara, Primo N. Jr MD 9,; Vaishampayan, Ulka N. MBBS 10,; Zhang, Jingsong MD, PhD 11,; Paul, Asit K. MD, PhD 12,; Bubley, Glenn MD 13; Van Allen, Eliezer M. MD 5,; Unlu, Serhan MD 1; Huang, Ying MD, PhD 5,; Loda, Massimo MD 14,; Shapiro, Geoffrey I. MD, PhD 5; Glazer, Peter M. MD, PhD 15,; LoRusso, Patricia M. DO 1,; Ivy, S. Percy MD 16; Shyr, Yu PhD 4,; Swisher, Elizabeth M. MD 3,; Petrylak, Daniel P. MD 1,
doi : 10.1200/JCO.21.02947
Cediranib, a pan-vascular endothelial growth factor receptor inhibitor, suppresses expression of homologous recombination repair (HRR) genes and increases sensitivity to poly-(ADP-ribose) polymerase inhibition in preclinical models.
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ma, Ting Martin MD, PhD 1,; Sun, Yilun PhD 2; Malone, Shawn MD 3,; Roach, Mack III MD 4,; Dearnaley, David MD 5,6,; Pisansky, Thomas M. MD 7; Feng, Felix Y. MD 4,; Sandler, Howard M. MD 8,; Efstathiou, Jason A. MD, PhD 9,; Syndikus, Isabel MD 10,; Hall, Emma C. MD 11,; Tree, Alison C. MD 12,; Sydes, Matthew R. MSc 13,; Cruickshank, Claire BSc 11; Roy, Soumyajit MD 14; Bolla, Michel MD 15; Maingon, Philippe MD 16,; De Reijke, Theo MD 17; Nabid, Abdenour MD 18,; Carrier, Nathalie MSc 18; Souhami, Luis MD 19,; Zapatero, Almudena MD, PhD 20,; Guerrero, Araceli MD 21; Alvarez, Ana MD 22,; Gonzalez San-Segundo, Carmen MD, PhD 22; Maldonado, Xavier MD 23,; Romero, Tahmineh MSc 24; Steinberg, Michael L. MD 1,; Valle, Luca F. MD 1; Rettig, Matthew B. MD 25,26,; Nickols, Nicholas G. MD, PhD 1,; Shoag, Jonathan E. MD 27,; Reiter, Robert E. MD 25,; Zaorsky, Nicholas G. MD 28; Jia, Angela Y. MD, PhD 28; Garcia, Jorge A. MD 29,; Spratt, Daniel E. MD 28,; Kishan, Amar U. MD 1,25,,; on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators
doi : 10.1200/JCO.22.00970
The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Pfisterer, Jacobus MD 1,,; Joly, Florence MD, PhD 2,; Kristensen, Gunnar MD 3; Rau, Joern MSc 4; Mahner, Sven MD 5,6,; Pautier, Patricia MD 7,; El-Balat, Ahmed MD 8,9,; Kurtz, Jean-Emmanuel MD 10,; Canzler, Ulrich MD 11; Sehouli, Jalid MD 12,; Heubner, Martin L. MD 13,14,; Hartkopf, Andreas D. MD 15,16,; Baumann, Klaus MD 17,18; Hasenburg, Annette MD 19,20,; Hanker, Lars C. MD 21,; Belau, Antje MD 22,23,; Schmalfeldt, Barbara MD 24,25,; Denschlag, Dominik MD 26,; Park-Simon, Tjoung-Won MD 27,; Selle, Frederic MD 28,; Jackisch, Christian MD 29,; Burges, Alexander MD 6,; Luck, Hans-Joachim MD 30,; Emons, Gunter MD 31; Meier, Werner MD 32,33; Gropp-Meier, Martina MD 34; Schroder, Willibald MD 35; de Gregorio, Nikolaus MD 36,37,; Hilpert, Felix MD 38,39,; Harter, Philipp MD 40,
doi : 10.1200/JCO.22.01010
To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer.
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
Nastoupil, Loretta J. MD 1,,; Bartlett, Nancy L. MD 2,
doi : 10.1200/JCO.22.01848
AB Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases.
Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline.
Paice, Judith A. PhD, RN 1; Bohlke, Kari ScD 2; Barton, Debra PhD, RN 3,; Craig, David S. PharmD 4,; El-Jawahri, Areej MD 5,; Hershman, Dawn L. MD, MS 6,; Kong, Lynn R. MD 7; Kurita, Geana P. PhD, MNSc 8,; LeBlanc, Thomas W. MD 9,; Mercadante, Sebastiano MD 10; Novick, Kristina L. M. MD, MS 11; Sedhom, Ramy MD 12; Seigel, Carole MBA 13; Stimmel, Joanna PhD 14; Bruera, Eduardo MD 15,
doi : 10.1200/JCO.22.02198
To provide guidance on the use of opioids to manage pain from cancer or cancer treatment in adults. METHODS: A systematic review of the literature identified systematic reviews and randomized controlled trials of the efficacy and safety of opioid analgesics in people with cancer, approaches to opioid initiation and titration, and the prevention and management of opioid adverse events.
Final Report of EORTC 26951 and RTOG 9402 for Anaplastic Oligodendroglial Tumors.
Zhao, Binghao MD, PhD; Wu, Jiaming MD; Li, Huanzhang MD; Ma, Wenbin MD
doi : 10.1200/JCO.22.01492
Reply to B. Zhao et al.
Polley, Mei-Yin C. PhD; Gorlia, Thierry PhD; Lassman, Andy B. MD; van den Bent, Martin J. MD
doi : 10.1200/JCO.22.01874
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
Marchetti, Claudia MD, PhD; Fagotti, Anna MD, PhD; Scambia, Giovanni MD
doi : 10.1200/JCO.22.01585
Reply to C. Marchetti et al.
Monk, Bradley J. MD; Fujiwara, Keiichi MD; O'Malley, David M. MD; Coleman, Robert L. MD; McNeish, Iain A. MD; Lin, Kevin K. PhD; Hume, Stephanie PhD; Kristeleit, Rebecca S. MD
doi : 10.1200/JCO.22.01832
Progression-Free Survival or Failure of Local Treatment Strategy: End Points for Trials Testing Stereotactic Body Radiotherapy.
Widder, Joachim MD, PhD
doi : 10.1200/JCO.22.01246
Reply to J. Widder.
Chmura, Steven J. MD, PhD; Woodward, Wendy A. MD, PhD; White, Julia R. MD
doi : 10.1200/JCO.22.01764
Flashback Foreword: Single-Agent Anti-Programmed Cell Death Protein 1 Therapy for Refractory Solid Tumors.
Maki, Robert G. MD, PhD 1,2,,
doi : 10.1200/JCO.22.02437
Volume 41(4) pgs. 713-940 February 1, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Brahmer, Julie R.; Drake, Charles G.; Wollner, Ira; Powderly, John D.; Picus, Joel; Sharfman, William H.; Stankevich, Elizabeth; Pons, Alice; Salay, Theresa M.; McMiller, Tracee L.; Gilson, Marta M.; Wang, Changyu; Selby, Mark; Taube, Janis M.; Anders, Robert; Chen, Lieping; Korman, Alan J.; Pardoll, Drew M.; Lowy, Israel; Topalian, Suzanne L.
doi : 10.1200/JCO.22.02270
Programmed death-1 (PD-1), an inhibitory receptor expressed on activated T cells, may suppress antitumor immunity. This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates.
Management of Diffuse Large B-Cell Lymphoma: Are We Getting Smarter?.
Kahl, Brad S. MD 1,,
doi : 10.1200/JCO.22.01501
Learning About Mismatch Repair From a Rare Cancer Syndrome: A LOGICal Step Forward.
Kamihara, Junne MD, PhD 1,,; Collins, Natalie B. MD, PhD 1,
doi : 10.1200/JCO.22.01678
Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets.
Santa-Maria, Cesar A. MD 1,,; Wolff, Antonio C. MD 1,
doi : 10.1200/JCO.22.02217
Immunotherapy, Chemotherapy, or Both: Options for First-Line Therapy for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Ho, Alan L. MD, PhD 1,2,
doi : 10.1200/JCO.22.01408
AB The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches.
Freeing the Competition: Will Aumolertinib (AENEAS) Have a Fighting Chance Against Osimertinib (FLAURA)?.
Benjamin, David J. MD 1; Nagasaka, Misako MD, PhD 2,3,
doi : 10.1200/JCO.22.01199
Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
Westin, Jason MD, MS 1,,; Davis, R. Eric MD 1,; Feng, Lei MS 2; Hagemeister, Fredrick MD 1,; Steiner, Raphael MD 1,; Lee, Hun Ju MD 1,; Fayad, Luis MD 1,; Nastoupil, Loretta MD 1,; Ahmed, Sairah MD 1,; Rodriguez, Alma MD 1; Fanale, Michelle MD 1,3,; Samaniego, Felipe MD 1,; Iyer, Swaminathan P. MD 1,; Nair, Ranjit MD 1,; Oki, Yasuhiro MD 1,; Fowler, Nathan MD 1,; Wang, Michael MD 1,; Ma, Man Chun John PhD 1; Vega, Francisco MD 4,; McDonnell, Timothy MD 4; Pinnix, Chelsea MD, PhD 5,; Griffith, Donna RN 1; Lu, Yang MD 6,; Tewari, Sanjit MD 6,; Sun, Ryan PhD 2,; Scott, David W. MBChB, PhD 7,; Flowers, Christopher R. MD 1,; Neelapu, Sattva MD 1,; Green, Michael R. PhD 1,8,
doi : 10.1200/JCO.22.00597
Chemoimmunotherapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) is largely unchanged for decades. Both preclinical models and clinical data suggest the combination of lenalidomide and ibrutinib may have synergy in DLBCL, particularly in the non-germinal center B-cell-like subset.
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.
Grob, Tim MD 1; Sanders, Mathijs A. PhD 1; Vonk, Christian M. MSc 1; Kavelaars, Fran[Cyrillic small letter es with descender]ois G. BSc 1; Rijken, Melissa BSc 1; Hanekamp, Diana W. PhD 1,2; Gradowska, Patrycja L. PhD 1; Cloos, Jacqueline PhD 2,; Floisand, Yngvar MD, PhD 3,; van Marwijk Kooy, Marinus MD, PhD 4; Manz, Markus G. MD 5; Ossenkoppele, Gert J. MD, PhD 2,; Tick, Lidwine W. MD, PhD 6; Havelange, Violaine MD, PhD 7,; Lowenberg, Bob MD, PhD 1,; Jongen-Lavrencic, Mojca MD, PhD 1; Valk, Peter J.M. PhD 1,,
doi : 10.1200/JCO.22.00715
The applicability of FLT3-internal tandem duplications (FLT3-ITD) for assessing measurable residual disease (MRD) in acute myeloid leukemia (AML) in complete remission (CR) has been hampered by patient-specific duplications and potential instability of FLT3-ITD during relapse.
Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset.
Chung, Jiil PhD 1,2; Negm, Logine 1,2,3; Bianchi, Vanessa PhD 2; Stengs, Lucie 2; Das, Anirban MD 1,2,4,5; Liu, Zhihui Amy PhD 6,7; Sudhaman, Sumedha PhD 1,2,; Aronson, Melyssa MSc 8; Brunga, Ledia MD 1,9; Edwards, Melissa PhD 1; Forster, Victoria PhD 2; Komosa, Martin MSc 2; Davidson, Scott PhD 1,9; Lees, Jodi 1; Tomboc, Patrick MD 10,; Samuel, David MD 11; Farah, Roula MD 12; Bendel, Anne MD 13; Knipstein, Jeffrey MD 14,; Schneider, Kami Wolfe MSc 15,; Reschke, Agnes MD 16; Zelcer, Shayna MD 17; Zorzi, Alexandra MD 18; McWilliams, Robert MD 19,; Foulkes, William D. MD 20; Bedgood, Raymond MD 21; Peterson, Lindsay MD 22,; Rhode, Sara MSc 23,; Van Damme, An MD 24,; Scheers, Isabelle MD 25; Gardner, Sharon MD 26; Robbins, Gabriel MD 26; Vanan, Magimairajan Issai MD 27,28; Meyn, M. Stephen MD, PhD 29,30,; Auer, Rebecca MD 31,; Leach, Brandie MSc 32,; Burke, Carol MD 32,; Villani, Anita MD 4; Malkin, David MD 4,; Bouffet, Eric MD 4,; Huang, Annie MD, PhD 2,4,33; Taylor, Michael D. MD, PhD 2,34; Durno, Carol MD 8,35; Shlien, Adam PhD 1,9,33; Hawkins, Cynthia MD, PhD 2,9,36,; Getz, Gad PhD 37,38,39,40,; Maruvka, Yosef E. PhD 41,; Tabori, Uri MD 1,2,4,; on behalf of the International Replication Repair Deficiency Consortium
doi : 10.1200/JCO.21.02873
Diagnosis of Mismatch Repair Deficiency (MMRD) is crucial for tumor management and early detection in patients with the cancer predisposition syndrome constitutional mismatch repair deficiency (CMMRD).
Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/DICER1 Registry.
Schultz, Kris Ann P. MD 1,2,3,; Harris, Anne K. MPH 1,2,3; Nelson, Alexander T. BS 1,2,3,4; Watson, Dave PhD 5,; Lucas, John T. Jr MS, MD 6; Miniati, Doug MD 7; Stewart, Douglas R. MD 8,; Hagedorn, Kelly N. MD 9,; Mize, William MD 9; Kamihara, Junne MD, PhD 10,; Mitchell, Sarah G. MD 11; Wilson, David B. MD, PhD 12,; Gettinger, Katie CPNP 12; Rangaswami, Arun A. MD 13; Harney, Laura A. BSN 14; Rodriguez Galindo, Carlos MD 15; Bisogno, Gianni MD 16,; Dehner, Louis P. MD 17; Hill, D. Ashley MD 18,19,; Messinger, Yoav H. MD 1,2,3
doi : 10.1200/JCO.21.02925
Pleuropulmonary blastoma (PPB) is the most common primary lung neoplasm of infancy and early childhood. Type II and type III PPB have historically been associated with a poor prognosis.
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington, Kevin J. PhD 1,,; Burtness, Barbara MD 2,; Greil, Richard MD 3,4,; Soulieres, Denis MD 5,; Tahara, Makoto MD 6,; de Castro, Gilberto Jr MD 7,; Psyrri, Amanda MD 8,; Brana, Irene MD 9,; Baste, Neus MD 9,; Neupane, Prakash MD 10,; Bratland, Ase PhD 11,; Fuereder, Thorsten MD 12,; Hughes, Brett G.M. MBBS 13,; Mesia, Ricard PhD 14,; Ngamphaiboon, Nuttapong MD 15,; Rordorf, Tamara MD 16; Wan Ishak, Wan Zamaniah MD 17,; Lin, Jianxin MS 18,; Gumuscu, Burak MD 18,; Swaby, Ramona F. MD 18,; Rischin, Danny MD 19,20,
doi : 10.1200/JCO.21.02508
Pembrolizumab and pembrolizumab-chemotherapy demonstrated efficacy in recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048. Post hoc analysis of long-term efficacy and progression-free survival on next-line therapy (PFS2) is presented.
Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials.
Gallois, Claire MD 1,; Shi, Qian PhD 2,; Meyers, Jeffrey P. MD 2,; Iveson, Timothy MD 3,; Alberts, Steven R. MD, MPH 4; de Gramont, Aimery MD 5; Sobrero, Alberto F. PhD 6,; Haller, Daniel G. MD 7; Oki, Eiji MD 8,; Shields, Anthony Frank MD, PhD 9,; Goldberg, Richard M. MD 10,; Kerr, Rachel MD 11; Lonardi, Sara MD 12,; Yothers, Greg PhD 13,; Kelly, Caroline PhD 14; Boukovinas, Ioannis MD, PhD 15,; Labianca, Roberto MD 16,; Sinicrope, Frank A. MD 4,; Souglakos, Ioannis MD, PhD 17,; Yoshino, Takayuki MD 18,; Meyerhardt, Jeffrey A. MD, MPH 19,; Andre, Thierry MD, PhD 20,; Papamichael, Demetris MD 21,; Taieb, Julien MD, PhD 1,,
doi : 10.1200/JCO.21.02726
Oxaliplatin-based adjuvant chemotherapy in patients with stage III colon cancer (CC) for 6 months remains a standard in high-risk stage III patients. Data are lacking as to whether early discontinuation of all treatment (ETD) or early discontinuation of oxaliplatin (EOD) could worsen the prognosis.
Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients With Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial.
Yamaguchi, Kensei MD 1,,; Bang, Yung-Jue MD, PhD 2,; Iwasa, Satoru MD 3,; Sugimoto, Naotoshi MD 4,; Ryu, Min-Hee MD, PhD 5,; Sakai, Daisuke MD 6,; Chung, Hyun Cheol MD, PhD 7,; Kawakami, Hisato MD, PhD 8,; Yabusaki, Hiroshi MD 9; Lee, Jeeyun MD 10,; Shimoyama, Tatsu MD 11; Lee, Keun-Wook MD, PhD 12,; Saito, Kaku MSc, MBA 13,; Kawaguchi, Yoshinori MSc, MBA 13,; Kamio, Takahiro MD 13,; Kojima, Akihito MSc 14,; Sugihara, Masahiro PhD 14,; Shitara, Kohei MD 15,
doi : 10.1200/JCO.22.00575
To investigate efficacy and safety of trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-low gastric or gastroesophageal junction (GEJ) adenocarcinoma.
A Two-Step Frailty Assessment Strategy in Older Patients With Solid Tumors: A Decision Curve Analysis.
Gonzalez Serrano, Adolfo MD, MSc 1,; Laurent, Marie MD, PhD 1,2; Barnay, Thomas PhD 3; Martinez-Tapia, Claudia PhD 1; Audureau, Etienne MD, PhD 1,4; Boudou-Rouquette, Pascaline MD 5,; Aparicio, Thomas MD, PhD 6,; Rollot-Trad, Florence MD 7; Soubeyran, Pierre MD, PhD 8,; Bellera, Carine PhD 9,10,; Caillet, Philippe MD 1,11,12,; Paillaud, Elena MD, PhD 1,11,12,; Canoui-Poitrine, Florence MD, PhD 1,4
doi : 10.1200/JCO.22.01118
The intended clinical value of frailty screening is to identify unfit patients needing geriatric assessment (GA) and to prevent unnecessary GA in fit patients. These hypotheses rely on the sensitivity and specificity of screening tests, but they have not been verified.
Effects of a Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Older Adults With Advanced Cancer.
Culakova, Eva PhD, MS 1; Mohile, Supriya G. MD, MS 2; Peppone, Luke PhD, MPH 1,2,; Ramsdale, Erika MD, MS 2,; Mohamed, Mostafa MBBCh 2,3; Xu, Huiwen PhD 4; Wells, Megan MPH 2,; Tylock, Rachael MS 2,; Java, Jim PhD 5; Loh, Kah Poh MBBCh, BAO, MS 2,; Magnuson, Allison DO, MS 2; Jamieson, Leah RN 6; Vogel, Victor MD 7; Duberstein, Paul R. PhD 8; Chapman, Benjamin P. PhD, MPH, MS 9; Dale, William MD, PhD 10; Flannery, Marie Anne PhD, RN 11,
doi : 10.1200/JCO.22.00738
Providing a geriatric assessment (GA) summary with management recommendations to oncologists reduces clinician-rated toxicity in older patients with advanced cancer receiving treatment. This secondary analysis of a national cluster randomized clinical trial (ClinicalTrials.
Impact of Geriatric Assessment and Management on Quality of Life, Unplanned Hospitalizations, Toxicity, and Survival for Older Adults With Cancer: The Randomized 5C Trial.
Puts, Martine RN, PhD, FAAN 1,; Alqurini, Naser MD, MRCGP (INT) 2; Strohschein, Fay RN, PhD 3; Koneru, Rama MBBS, FRCPC, MHSc 4,; Szumacher, Ewa MD, FRCPC, MEd, CPC(HC) 5; Mariano, Caroline MD, FRCPC 6,; Monette, Johanne MD, MSc 7; Hsu, Tina MD, FRCPC, MMEd 8,; Brennenstuhl, Sarah MSW, PhD 1; McLean, Bianca MD 1,9; Wills, Aria BSc 1; Berger, Arielle MD 10; Amir, Eitan MD, PhD 11,12,; Romanovsky, Lindy MD, MSc (HQ) 10; Li, Anson MD, MSc 13; Mehta, Rajin MD, FRCPC, FRCPE 14; Krzyzanowska, Monika MD, MPH 11,; Elser, Christine MD, MPhil 11,12; Jang, Raymond MD, MSc 11,; Prica, Anca MD, MSc 11,; Wan-Chow-Wah, Doreen MDCM, FRCPC 7; Pitters, Eric BSc 1; Emmenegger, Urban MD 15,; Menjak, Ines B. MD, MSc, FRCPC 15,; Bergman, Simon MD, MSc 16; Lemonde, Manon RN, PhD 17; Breunis, Henriette CCRP 18; Beland, Francois PhD 19; Alibhai, Shabbir M.H. MD, MSc 20,
doi : 10.1200/JCO.22.01007
American Society of Clinical Oncology recommends that older adults with cancer being considered for chemotherapy receive geriatric assessment (GA) and management (GAM), but few randomized controlled trials have examined its impact on quality of life (QOL).
Reassessing the Benefits and Harms of Risk-Reducing Medication Considering the Persistent Risk of Breast Cancer Mortality in Estrogen Receptor-Positive Breast Cancer.
Jayasekera, Jinani PhD 1,; Zhao, Amy MSc 2; Schechter, Clyde MD 3; Lowry, Kathryn MD 4; Yeh, Jennifer M. PhD 5; Schwartz, Marc D. PhD 2; O'Neill, Suzanne PhD 2,; Wernli, Karen J. PhD 6; Stout, Natasha PhD 7; Mandelblatt, Jeanne MD 2; Kurian, Allison W. MD, MSc 8,; Isaacs, Claudine MD 2,
doi : 10.1200/JCO.22.01342
Recent studies, including a meta-analysis of 88 trials, have shown higher than expected rates of recurrence and death in hormone receptor-positive breast cancer. These new findings suggest a need to re-evaluate the use of risk-reducing medication to avoid invasive breast cancer and breast cancer death in high-risk women.
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984.
Kim, Joseph W. MD 1,,; McKay, Rana R. MD 2,; Radke, Marc R. BS 3; Zhao, Shilin PhD 4; Taplin, Mary-Ellen MD 5,; Davis, Nancy B. MD 6,; Monk, Paul MD 7,; Appleman, Leonard J. MD, PhD 8,; Lara, Primo N. Jr MD 9,; Vaishampayan, Ulka N. MBBS 10,; Zhang, Jingsong MD, PhD 11,; Paul, Asit K. MD, PhD 12,; Bubley, Glenn MD 13; Van Allen, Eliezer M. MD 5,; Unlu, Serhan MD 1; Huang, Ying MD, PhD 5,; Loda, Massimo MD 14,; Shapiro, Geoffrey I. MD, PhD 5; Glazer, Peter M. MD, PhD 15,; LoRusso, Patricia M. DO 1,; Ivy, S. Percy MD 16; Shyr, Yu PhD 4,; Swisher, Elizabeth M. MD 3,; Petrylak, Daniel P. MD 1,
doi : 10.1200/JCO.21.02947
Cediranib, a pan-vascular endothelial growth factor receptor inhibitor, suppresses expression of homologous recombination repair (HRR) genes and increases sensitivity to poly-(ADP-ribose) polymerase inhibition in preclinical models.
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials.
Ma, Ting Martin MD, PhD 1,; Sun, Yilun PhD 2; Malone, Shawn MD 3,; Roach, Mack III MD 4,; Dearnaley, David MD 5,6,; Pisansky, Thomas M. MD 7; Feng, Felix Y. MD 4,; Sandler, Howard M. MD 8,; Efstathiou, Jason A. MD, PhD 9,; Syndikus, Isabel MD 10,; Hall, Emma C. MD 11,; Tree, Alison C. MD 12,; Sydes, Matthew R. MSc 13,; Cruickshank, Claire BSc 11; Roy, Soumyajit MD 14; Bolla, Michel MD 15; Maingon, Philippe MD 16,; De Reijke, Theo MD 17; Nabid, Abdenour MD 18,; Carrier, Nathalie MSc 18; Souhami, Luis MD 19,; Zapatero, Almudena MD, PhD 20,; Guerrero, Araceli MD 21; Alvarez, Ana MD 22,; Gonzalez San-Segundo, Carmen MD, PhD 22; Maldonado, Xavier MD 23,; Romero, Tahmineh MSc 24; Steinberg, Michael L. MD 1,; Valle, Luca F. MD 1; Rettig, Matthew B. MD 25,26,; Nickols, Nicholas G. MD, PhD 1,; Shoag, Jonathan E. MD 27,; Reiter, Robert E. MD 25,; Zaorsky, Nicholas G. MD 28; Jia, Angela Y. MD, PhD 28; Garcia, Jorge A. MD 29,; Spratt, Daniel E. MD 28,; Kishan, Amar U. MD 1,25,,; on behalf of the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators
doi : 10.1200/JCO.22.00970
The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT).
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III Trial.
Pfisterer, Jacobus MD 1,,; Joly, Florence MD, PhD 2,; Kristensen, Gunnar MD 3; Rau, Joern MSc 4; Mahner, Sven MD 5,6,; Pautier, Patricia MD 7,; El-Balat, Ahmed MD 8,9,; Kurtz, Jean-Emmanuel MD 10,; Canzler, Ulrich MD 11; Sehouli, Jalid MD 12,; Heubner, Martin L. MD 13,14,; Hartkopf, Andreas D. MD 15,16,; Baumann, Klaus MD 17,18; Hasenburg, Annette MD 19,20,; Hanker, Lars C. MD 21,; Belau, Antje MD 22,23,; Schmalfeldt, Barbara MD 24,25,; Denschlag, Dominik MD 26,; Park-Simon, Tjoung-Won MD 27,; Selle, Frederic MD 28,; Jackisch, Christian MD 29,; Burges, Alexander MD 6,; Luck, Hans-Joachim MD 30,; Emons, Gunter MD 31; Meier, Werner MD 32,33; Gropp-Meier, Martina MD 34; Schroder, Willibald MD 35; de Gregorio, Nikolaus MD 36,37,; Hilpert, Felix MD 38,39,; Harter, Philipp MD 40,
doi : 10.1200/JCO.22.01010
To compare standard versus extended duration of bevacizumab treatment in combination with front-line chemotherapy in women with newly diagnosed stage IIB-IV ovarian cancer.
Navigating the Evolving Treatment Landscape of Diffuse Large B-Cell Lymphoma.
Nastoupil, Loretta J. MD 1,,; Bartlett, Nancy L. MD 2,
doi : 10.1200/JCO.22.01848
AB Diffuse large B-cell lymphoma, the most common subtype of non-Hodgkin lymphoma, comprises a heterogenous group of morphologically, genetically, and clinically distinct diseases.
Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline.
Paice, Judith A. PhD, RN 1; Bohlke, Kari ScD 2; Barton, Debra PhD, RN 3,; Craig, David S. PharmD 4,; El-Jawahri, Areej MD 5,; Hershman, Dawn L. MD, MS 6,; Kong, Lynn R. MD 7; Kurita, Geana P. PhD, MNSc 8,; LeBlanc, Thomas W. MD 9,; Mercadante, Sebastiano MD 10; Novick, Kristina L. M. MD, MS 11; Sedhom, Ramy MD 12; Seigel, Carole MBA 13; Stimmel, Joanna PhD 14; Bruera, Eduardo MD 15,
doi : 10.1200/JCO.22.02198
To provide guidance on the use of opioids to manage pain from cancer or cancer treatment in adults. METHODS: A systematic review of the literature identified systematic reviews and randomized controlled trials of the efficacy and safety of opioid analgesics in people with cancer, approaches to opioid initiation and titration, and the prevention and management of opioid adverse events.
Final Report of EORTC 26951 and RTOG 9402 for Anaplastic Oligodendroglial Tumors.
Zhao, Binghao MD, PhD; Wu, Jiaming MD; Li, Huanzhang MD; Ma, Wenbin MD
doi : 10.1200/JCO.22.01492
Reply to B. Zhao et al.
Polley, Mei-Yin C. PhD; Gorlia, Thierry PhD; Lassman, Andy B. MD; van den Bent, Martin J. MD
doi : 10.1200/JCO.22.01874
Rucaparib Maintenance in Upfront Ovarian Cancer: The Long-Lasting Challenge of Predicting Response to Poly (ADP-ribose) Polymerase Inhibitors.
Marchetti, Claudia MD, PhD; Fagotti, Anna MD, PhD; Scambia, Giovanni MD
doi : 10.1200/JCO.22.01585
Reply to C. Marchetti et al.
Monk, Bradley J. MD; Fujiwara, Keiichi MD; O'Malley, David M. MD; Coleman, Robert L. MD; McNeish, Iain A. MD; Lin, Kevin K. PhD; Hume, Stephanie PhD; Kristeleit, Rebecca S. MD
doi : 10.1200/JCO.22.01832
Progression-Free Survival or Failure of Local Treatment Strategy: End Points for Trials Testing Stereotactic Body Radiotherapy.
Widder, Joachim MD, PhD
doi : 10.1200/JCO.22.01246
Reply to J. Widder.
Chmura, Steven J. MD, PhD; Woodward, Wendy A. MD, PhD; White, Julia R. MD
doi : 10.1200/JCO.22.01764
